HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights

Barbara L Shacklett¹, Cynthia A Derdeyn², Morenike Oluwatoyin Folayan³, Raphael J Landovitz⁴, Colin Anthony⁵, Anna-Janina Behrens⁶, Thomas J Hope⁷, Elise Landais^{8

9}, Lorna Leal¹⁰, Jeanne M Marrazzo¹¹, Lynn Morris¹², Nelly Mugo¹³, Kenneth Ngure¹⁴, Veronica Noseda¹⁵, Srinika Ranasinghe¹⁶, Damien C Tully¹⁶, Yegor Voronin¹⁷, Mitchell Warren¹⁸, Constantinos Kurt Wibmer¹⁹, Irene Y Xie²⁰, Gabriella Scarlatti¹⁷, Bargavi Thyagarajan¹⁷

Affiliations

¹ 1 Department of Medical Microbiology and Immunology and Division of Infectious Diseases, Department of Medicine, School of Medicine, University of California at Davis , Davis, California.
² 2 Department of Pathology and Laboratory Medicine, Emory University , Atlanta, Georgia .
³ 3 Department of Child Dental Health, Obafemi Awolowo University , Ile-Ife, New HIV Vaccine and Microbicide Advocacy Society, Lagos, Nigeria .
⁴ 4 Division of Infectious Diseases, UCLA Center for Clinical AIDS Research & Education, University of California , Los Angeles, California.
⁵ 5 Division of Medical Virology, Department of Pathology, Faculty of Health Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town , Cape Town, South Africa .
⁶ 6 Department of Biochemistry, Oxford Glycobiology Institute, University of Oxford , Oxford, United Kingdom .
⁷ 7 Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University , Chicago, Illinois.
⁸ 8 International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute , La Jolla, California.
⁹ 9 International AIDS Vaccine Initiative , New York, New York.
¹⁰ 10 Hospital Clínic de Barcelona-IDIBAPS , Barcelona, Spain .
¹¹ 11 Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham School of Medicine , Birmingham, Alabama.
¹² 12 National Institute for Communicable Diseases , Johannesburg, South Africa .
¹³ 13 Center for Clinical Research, Kenya Medical Research Institute , Nairobi, Kenya .
¹⁴ 14 Department of Public and Community Health, Jomo Kenyatta University of Agriculture and Technology , Nairobi, Kenya .
¹⁵ 15 Planned Parenthood France/Le Planning Familial , Paris, France .
¹⁶ 16 Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University , Cambridge, Massachusetts.
¹⁷ 17 Global HIV Vaccine Enterprise , New York, New York.
¹⁸ 18 AVAC , New York, New York.
¹⁹ 19 Faculty of Health Sciences, Centre for HIV and STIs, National Institute for Communicable Diseases (NICD), of the National Health Laboratory Service (NHLS), University of the Witwatersrand , Johannesburg, South Africa .
²⁰ 20 National HIV and Retrovirology Labs, Department of Medical Microbiology and Infectious Diseases, JC Wilt Center for Infectious Diseases, Public Health Agency of Canada, University of Manitoba , Winnipeg, Canada .

PMID: 28649869
PMCID: PMC5564036
DOI: 10.1089/AID.2017.0125

HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights

Barbara L Shacklett et al. AIDS Res Hum Retroviruses. 2017 Aug.

. 2017 Aug;33(8):749-759.

doi: 10.1089/AID.2017.0125. Epub 2017 Jul 26.

Authors

Affiliations

¹ 1 Department of Medical Microbiology and Immunology and Division of Infectious Diseases, Department of Medicine, School of Medicine, University of California at Davis , Davis, California.
² 2 Department of Pathology and Laboratory Medicine, Emory University , Atlanta, Georgia .
³ 3 Department of Child Dental Health, Obafemi Awolowo University , Ile-Ife, New HIV Vaccine and Microbicide Advocacy Society, Lagos, Nigeria .
⁴ 4 Division of Infectious Diseases, UCLA Center for Clinical AIDS Research & Education, University of California , Los Angeles, California.
⁵ 5 Division of Medical Virology, Department of Pathology, Faculty of Health Sciences, Institute of Infectious Disease and Molecular Medicine, University of Cape Town , Cape Town, South Africa .
⁶ 6 Department of Biochemistry, Oxford Glycobiology Institute, University of Oxford , Oxford, United Kingdom .
⁷ 7 Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University , Chicago, Illinois.
⁸ 8 International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute , La Jolla, California.
⁹ 9 International AIDS Vaccine Initiative , New York, New York.
¹⁰ 10 Hospital Clínic de Barcelona-IDIBAPS , Barcelona, Spain .
¹¹ 11 Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham School of Medicine , Birmingham, Alabama.
¹² 12 National Institute for Communicable Diseases , Johannesburg, South Africa .
¹³ 13 Center for Clinical Research, Kenya Medical Research Institute , Nairobi, Kenya .
¹⁴ 14 Department of Public and Community Health, Jomo Kenyatta University of Agriculture and Technology , Nairobi, Kenya .
¹⁵ 15 Planned Parenthood France/Le Planning Familial , Paris, France .
¹⁶ 16 Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University , Cambridge, Massachusetts.
¹⁷ 17 Global HIV Vaccine Enterprise , New York, New York.
¹⁸ 18 AVAC , New York, New York.
¹⁹ 19 Faculty of Health Sciences, Centre for HIV and STIs, National Institute for Communicable Diseases (NICD), of the National Health Laboratory Service (NHLS), University of the Witwatersrand , Johannesburg, South Africa .
²⁰ 20 National HIV and Retrovirology Labs, Department of Medical Microbiology and Infectious Diseases, JC Wilt Center for Infectious Diseases, Public Health Agency of Canada, University of Manitoba , Winnipeg, Canada .

PMID: 28649869
PMCID: PMC5564036
DOI: 10.1089/AID.2017.0125

Abstract

HIV Research for Prevention: AIDS Vaccine, Microbicide, and ARV-based Prevention Science (HIVR4P) was built on a growing consensus that effective HIV prevention requires a combination of approaches and that understanding, analyzing, and debating the cross-cutting issues that impact prevention research are all essential to combat the global HIV/AIDS epidemic. To that end, the biennial HIVR4P conference is dedicated to all biomedical HIV prevention research approaches, including HIV vaccines, microbicides, pre-exposure prophylaxis, and treatment as prevention. The HIVR4P 2016 conference was held in Chicago, Illinois (USA), on October 17-21, and included more than 700 scientific presentations and 21 satellite sessions covering the latest and most promising advances across the HIV prevention research field. The theme "Partnering for Prevention" represented the conference's commitment to breaking down silos between research disciplines as well as between researchers, program developers, care providers, advocates, communities, and funders. Delegates spanning 42 countries attended the conference. One-third of those in attendance were early career investigators, which reflects a firm commitment to emerging researchers and ultimately to the goal of developing a sustainable scientific enterprise well into the future. This article presents a concise summary of highlights from the conference. For a more detailed account, one may find full abstracts, daily summaries, and webcasts on the conference website at hivr4p.org.

Keywords: HIV prevention; PrEP; R4P; antibody; microbicide; vaccine.

PubMed Disclaimer

Conflict of interest statement

No competing financial interests exist.

References

1. European Centre for Disease Prevention and Control (ECDC): HIV/AIDS Surveillance in Europe 2014. Stockholm, Sweden: WHO Regional Office for Europe; 2014
1. UNAIDS. AIDS Data. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2016
1. Abstracts of the HIV Research for Prevention Meeting, HIVR4P, 17–20 October, 2016, Chicago, USA: AIDS Res Hum Retroviruses; 2016;32(S1): 1–409 - PubMed
1. Abstracts From the 2016 Conference on Retroviruses and Opportunistic Infections: Top Antivir Med 2016;24(e-1):1–463 - PubMed
1. Scheid JF, et al. : HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 2016;535:556–560 - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

R13 AI122959/AI/NIAID NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights

Affiliations

HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous